Table 3.
Clinical trials involving PDT of cancers with 5-ALA and derivatives started between March of 2013 and March of 2023.
| Photosensitizer | DLI | Cancer | Phase | Status | Country | Observations | Reference | Study start |
|---|---|---|---|---|---|---|---|---|
| 5-ALA | 2 h * | Non-muscle invasive bladder cancer | N/A | Not yet recruiting | China | Combination standard infusion chemotherapy and surgery; PS infusion to bladder for 2h | NCT05547516 | September 2022 |
| N/A | Skin tumors and non-cancer skin disorders | N/A | Recruiting | China | PS topical administ. with piezoelectric drive microneedling | NCT05488860 | July 2022 | |
| 6 h | Glioblastoma | II | Recruiting | Belgium, France | Intraoperative PDT; PS oral administ. | NCT04391062 | September 2021 | |
| 3.5–4.5 h | Glioblastoma | II | Recruiting | Germany | Stereotactic PDT; PS oral administ. | NCT04469699 | April 2021 | |
| 3h* | Superficial and nodular basal cell carcinoma | II | Recruiting | USA | PS topical administ. with jet injection | NCT04552990 | September 2020 | |
| N/A | Basal cell carcinoma; Basal cell nevus syndrome | I | Active, not recruiting | USA | Combination with oral Vit.D3 pre-treatment | NCT03467789 | October 2018 | |
| 3 h* | Superficial basal cell carcinoma | III | Recruiting | USA | Illumination with BF-Foscan®; PS topical administ. | NCT03573401 | September 2018 | |
| 3h* | Skin cancer non-melanoma; skin cancer sun damaged skin; Actinic keratoses |
I/II | Recruiting | USA | PS topical administ. | NCT03110159 | August 2017 | |
| 4 h | Glioblastoma | N/A | Completed | France | Per-operative PDT; PS oral administ. | NCT03048240 | May 2017 | |
| 0 - 2h | Head and neck | I/II | Completed | India | PS oral administ. at 0, 1 and 2 h before illumination | NCT03638622 | March 2017 | |
| 3 h* | Squamous cell carcinoma | N/A | Unknown | USA | Surgical excision vs PDT; PS topical administ. | NCT03025724 | January 2017 | |
| 2.5 h* | Nonmelanoma skin cancers in organ transplant recipients | N/A | Completed | USA | PS topical administ. | NCT02751151 | February 2016 | |
| 5-ALA and MAL | N/A | Basal cell carcinoma | I | Completed | USA | ALA + Vismodegib vs MAL + Vismodegib |
NCT02639117 | November 2015 |
| 3 h* | Basal cell carcinoma | III | Completed | Germany | BF-200 ALA (Ameluz ®) vs Methyl-aminolevulinate (Metvix ®); PS topical administ. | NCT02144077 | January 2014 | |
| 4 h* | Superficial basal cell carcinoma | IV | Unknown | Netherlands | 5-ALA vs MAL; PS topical administ. | NCT01491711 | August 2013 | |
| 5-ALA, MAL and HAL | N/A | Neoplasms; Basal cell carcinoma | I/II | Active, not recruiting | Finland | 5-ALA vs MAL vs HAL; PS topical administ. | NCT02367547 | March 2015 |
| MAL | 3h* | Superficial basal cell carcinoma; Bowen’s Disease | N/A | Completed | Belgium | Combination will full ablative CO2 laser vs fraction ablative CO2 laser; PS topical administ. | NCT03012009 | September 2014 |
(*) Time of occlusion or infusion.